Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316487 | 1.00 | HTR4 (1.00) | HTR4KCNH2 | |
| SCHEMBL3316483 | 1.00 | HTR4 (1.00) | HTR4KCNH2 | |
| SCHEMBL3316190 | 0.95 | HTR4 (0.91) | HTR4KCNH2 | |
| SCHEMBL3316184 | 0.95 | HTR4 (0.91) | HTR4KCNH2 | |
| SCHEMBL3316182 | 0.95 | HTR4 (0.91) | HTR4KCNH2 | |
| SCHEMBL3316741 | 0.95 | HTR4 (0.90) | HTR4KCNH2 | |
| SCHEMBL3316740 | 0.95 | HTR4 (0.90) | HTR4KCNH2 | |
| SCHEMBL3316753 | 0.95 | HTR4 (0.90) | HTR4KCNH2 | |
| SCHEMBL3313535 | 0.94 | HTR4 (1.00) | HTR4KCNH2 | |
| SCHEMBL3313529 | 0.94 | HTR4 (1.00) | HTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137152-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Dong-A Pharm.Co., Ltd. (KR) | 2009-12-30 | — | — | EP | claimed |
| WO-2008114971-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | DONG-A PHARM. CO., LTD. (KR) | 2008-09-25 | — | — | WO | claimed |
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-2137152-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Dong-A Pharm.Co., Ltd. (KR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114971-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | DONG-A PHARM. CO., LTD. (KR) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | HTR4 362/4885KCNH2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.